Curated News
By: NewsRamp Editorial Staff
May 07, 2024
Skye Bioscience Achieves Nasdaq Uplisting and Clinical Milestone
TLDR
- Skye Bioscience achieves uplisting to Nasdaq, enhancing visibility and investor base.
- SBI-100 OE, a cannabinoid receptor type 1 agonist, successfully dosed 56 patients in Phase 2a study for ocular diseases.
- Skye Bioscience's innovative therapy for ocular diseases signifies a significant milestone in advancing patient care.
- SBI-100 OE, a cannabinoid receptor type 1 agonist, administered topically to the eye, is designed to address the unmet needs of patients with elevated intraocular pressure related to primary open-angle glaucoma or ocular hypertension.
Impact - Why it Matters
The uplisting of Skye Bioscience's common stock to the Nasdaq exchange and the successful completion of dosing 56 patients with SBI-100 OE in its Phase 2a study mark significant milestones, signaling progress in the development of innovative therapies for ocular diseases. This achievement also reflects the company's commitment to enhancing visibility and unlocking value for shareholders as it advances in its clinical programs.
Summary
Skye Bioscience CEO Punit Dhillon announced the company's uplisting of its common stock to the Nasdaq exchange, reflecting advancements in its Phase 2 clinical programs and completion of dosing 56 patients with SBI-100 Ophthalmic Emulsion. This cannabinoid receptor type 1 agonist is designed to address the unmet needs of patients with elevated intraocular pressure related to glaucoma or ocular hypertension.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Skye Bioscience Achieves Nasdaq Uplisting and Clinical Milestone
